The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Abstract
LUX-Lung 7 compared afatinib and gefitinib as first-line therapy for common EGFR-mutant NSCLC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both afatinib and dacomitinib have shown significantly improved PFS versus gefitinib.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [42]
In the citing paper
“Serious treatment-related AEs were reported in 11% of afatinib-treated and 4% of gefitinib-treated patients”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [42]
In the citing paper
“Afatinib significantly improved PFS (median 11.0 vs 10.9 months; HR, 0.73 (95% CI, 0.57‒0.95), P = 0.017) and TTF (median 13.7 vs 11.5 months; HR, 0.73 (95% CI, 0.58‒0.92), P = 0.007) versus gefitinib.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [42]
In the citing paper
“Grade ≥3 diarrhea, rash/acne, and stomatitis were more frequent with afatinib, while elevated alanine aminotransferase/aspartate aminotransferase was more common with gefitinib.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [42]
In the citing paper
“In LUX-Lung 7, 50 patients with brain metastases (afatinib: n = 26; gefitinib: n = 24) showed similar PFS improvement between the two treatments (afatinib vs gefitinib: 7.2 vs 7.4 months; HR, 0.76 (95% CI, 0.41–1.44)) and also compared with patients without brain metastases.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [42]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationGefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationMitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Cited by
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
“Regimen Osimertinib (n=279) Standard EGFR-TKI (n=277) First post-treatment anticancer therapy (including cross-over osimertinib), n (%) Discontinued randomized trial treatment 138 (49) 213 (77) First post-treatment anticancer therapy 82 (29) 129 (47) No post-treatment anticancer therapy 56 (20) 84 (30) Ongoing randomi…”
BackgroundSelf-citationLung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
“Data on OS (co-primary end point) are still immature and data on QoL have not been presented [114].”
BackgroundPlanchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
“LUX-Lung 7 is a randomised phase IIB study that compares afatinib with gefitinib [181].”
BackgroundSelf-citationEpidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Metadata
- Authors
- Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., Shi, Y., Kim, S.-W., Laskin, J., Kim, D.-W., Arvis, C. D., Kölbeck, K., Laurie, S. A., Tsai, C.-M., Shahidi, M., Kim, M., Massey, D., Zazulina, V., & Paz-Ares, L.
- Affiliations
- Samsung Medical Center (KR)
- National Cancer Centre Singapore (SG)
- Sun Yat-sen University (CN)
- Chris O’Brien Lifehouse (AU)
- Chinese University of Hong Kong (HK)
- McGill University (CA)
- National Taiwan University Hospital (TW)
- Chungbuk National University Hospital (KR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Asan Medical Center (KR)
- BC Cancer Agency (CA)
- Seoul National University Hospital (KR)
- Centre François Baclesse (FR)
- Karolinska University Hospital (SE)
- Ottawa Hospital (CA)
- Taipei Veterans General Hospital (TW)
- Boehringer Ingelheim (United Kingdom) (GB)
- Boehringer Ingelheim (Germany) (DE)
- Spanish National Cancer Research Centre (ES)
- Corresponding author
- Park, Keunchil
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 17
- Issue
- 5
- Pages
- 577-589
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2339311613
- Semantic Scholar
- 1e54cc9c7b76b2ad1a90e9ff708082b354389d9a
- Cited by
- 1,183
- References
- 35
- Citations by year
- 2026: 47 · 2025: 71 · 2024: 90 · 2023: 108 · 2022: 140 · 2021: 159 · 2020: 133 · 2019: 133 · 2018: 123 · 2017: 118 · 2016: 59
- FWCI
- 129.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- afatinib, gefitinib, EGFR-mutant non-small cell lung cancer, first-line therapy, EGFR tyrosine kinase inhibitors, exon 19 deletion, progression-free survival, time to treatment failure, overall survival, brain metastases, treatment safety
- MeSH terms
- Gefitinib, Afatinib, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Male, Middle Aged, Mutation, Quinazolines, Disease-Free Survival, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Drug-Related Side Effects and Adverse Reactions, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(16)30033-x
- The paper
- Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., Shi, Y., Kim, S.-W., Laskin, J., Kim, D.-W., Arvis, C. D., Kölbeck, K., Laurie, S. A., Tsai, C.-M., Shahidi, M., . . . Paz-Ares, L. (2016). Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(16)30033-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.